Literature DB >> 11872238

Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon.

Rolf E Brouwer1, Pim van der Heiden, Geziena M T Schreuder, Arend Mulder, Gert Datema, Jacqy D H Anholts, Roel Willemze, Frans H J Claas, J H Frederik Falkenburg.   

Abstract

Human leukocyte antigen (HLA) class I expression at the allelic level was analyzed in 397 acute myeloid leukemia (AML) and 186 acute lymphoid leukemia (ALL) using a complement-dependent cytotoxicity assay. Impaired recognition possibly due to HLA downregulation was observed in 2% of the patients with AML and ALL in complete remission, and in 8%-15% in the groups with blasts. In 15 instances of diminished cytotoxicity, leukemic cells and control PHA blasts from the same patients were further analyzed using flow cytometry. In 4/6 ALL and 4/9 AML patients HLA downregulation or complete loss (2 patients) of cell surface expression could be confirmed. No genomic abnormalities were observed. In addition, 12 AML and 13 ALL patients were tested during relapse using flow cytometry. In 1/12 AML patients and 1/13 ALL patients allelic downregulation of cell surface expression was found. In two patients tested, downregulation or loss of cell surface expression of HLA class I antigens corresponded with impaired T cell mediated lysis by HLA restricted cytotoxic T lymphocyte.Treatment of the cells with alpha- or gamma-interferon could restore HLA class I expression and T-cell recognition. In conclusion, downregulation of cell surface expression of HLA class I expression at the allelic level in AML and ALL is infrequent but functionally relevant. HLA downregulation was reversible and T-cell recognition could be restored by alpha- or gamma-interferon.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872238     DOI: 10.1016/s0198-8859(01)00381-0

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  22 in total

1.  Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.

Authors:  Phuong Vo; Elaine S Jaffe; Lisa Cook; Catalina Ramos; Richard Childs
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08-30

Review 2.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

4.  The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia.

Authors:  Adam J de Smith; Kyle M Walsh; Martha B Ladner; Siming Zhang; Carmen Xiao; Franziska Cohen; Theodore B Moore; Anand P Chokkalingam; Catherine Metayer; Patricia A Buffler; Elizabeth A Trachtenberg; Joseph L Wiemels
Journal:  Blood       Date:  2014-02-11       Impact factor: 22.113

Review 5.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

6.  Analysis of HLA class Ia transcripts in human leukaemias.

Authors:  Durjoy Majumder; Debasis Bandyopadhyay; Sarmila Chandra; Ashis Mukhopadhayay; Nandini Mukherjee; Subir K Bandyopadhyay; Subrata Banerjee
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

7.  External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.

Authors:  Johannes Schetelig; Henning Baldauf; Falk Heidenreich; Carolin Massalski; Sandra Frank; Jürgen Sauter; Matthias Stelljes; Francis Ayuketang Ayuk; Wolfgang A Bethge; Gesine Bug; Stefan Klein; Sarah Wendler; Vinzenz Lange; Liesbeth C de Wreede; Daniel Fürst; Guido Kobbe; Hellmut D Ottinger; Dietrich W Beelen; Joannis Mytilineos; Katharina Fleischhauer; Alexander H Schmidt; Martin Bornhäuser
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

8.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

9.  Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors.

Authors:  Adiba Isa; Jan O Nehlin; Hardee J Sabir; Tom E Andersen; Michael Gaster; Moustapha Kassem; Torben Barington
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Authors:  David M Woods; Karrune Woan; Fengdong Cheng; Hongwei Wang; Patricio Perez-Villarroel; Calvin Lee; Maritza Lienlaf; Peter Atadja; Edward Seto; Jeffrey Weber; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Melanoma Res       Date:  2013-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.